Combining infliximab_ anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease.pdf

Fistulizing Crohn’s disease (CD) presents a therapeutic challenge as
fistulae are notoriously difficult to heal.
Nine consecutive patients with Crohn’s disease and fistulae were treated with a special combination of infliximab, numerous hyperbaric oxygen sessions and combined antibiotics including rifabutin, clofazimine and clarithromycin as the base antibiotic combination – called anti-Mycobacterium avium ss paratuberculosis (MAP) therapy. At between 6 weeks and 6 months all fistulae healed – included rectovaginal – so that the skin was dry and there was no discharge and no need to wear a pad. Their Crohn’s symptoms of diarrhea, urgency and bleeding also resolved.